<DOC>
	<DOCNO>NCT02819921</DOCNO>
	<brief_summary>This study randomize , placebo-controlled study desvenlafaxine versus placebo . The purpose study determine desvenlafaxine effective decreasing frequency severity hot flash breast cancer patient take tamoxifen .</brief_summary>
	<brief_title>Desvenlafaxine Treatment Hot Flashes Women With Breast Cancer Taking Tamoxifen</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>. Women age 18 year old localize breast cancer . Histologic documentation atypical ductal hyperplasia , ductal carcinoma situ ( DCIS ) , lobular carcinoma situ ( LCIS ) , invasive adenocarcinoma breast stage IIII A. ii . Current daily tamoxifen use . Any planned surgery , adjuvant chemotherapy radiation must complete . iii . History bothersome hot flush : â‰¥ 2 hot flushes/day , sufficiently severe intervention desire . Participants must bothersome hot flush least one month prior enrollment . . Women pregnant breast feeding , history seizure disorder hepatic renal insufficiency ii . Concurrent systemic hormone replacement therapy ( estrogen , progestational agent , androgen ) use corticosteroid iii . Concurrent use antidepressant , anxiolytic antipsychotic , gabapentin , pregabalin clonidine treatment hot flush depression . iv . Presence psychiatric disease beside depression disease affect immune system ( autoimmune disease include rheumatoid disease )</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hot Flashes</keyword>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Desvenlafaxine Succinate</keyword>
</DOC>